PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Category:
Sort By:
Aug 27, 2020
Aug 27, 2020

bybhenderson

Marietta, Ohio, August 27, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that Dr. James Shapiro has received approval from Health Canada and the...Read more
Aug 21, 2020
While there is currently no cure for diabetes, we believe our anti-aging glycopeptide, AAGP®, may be the essential link to the successful treatments of tomorrow. In preliminary testing, AAGP® has been...Read more
Marietta, Ohio, August 14, 2020                                                                                                         ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that due the results that AAGP® has achieved over the...Read more
Jul 20, 2020
For anyone living with Type 1 diabetes, there is no doubt it is a challenging illness. Type 1 diabetes occurs at no fault of the patient, but unfortunately, there is...Read more
Jul 14, 2020
When you are diagnosed with diabetes, you might initially feel overwhelmed and helpless. This chronic condition isn’t easy to live with all the time, since there are physical side effects...Read more
Jul 13, 2020
According to the Centers for Disease Control and Prevention (CDC), there were more than 30.3 million diagnosed cases of diabetes in the U.S. in 2015, and more than 100 million...Read more
Marietta, Ohio, July 13, 2020                                                                                                              ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced an update to the Press Release of March 24, 2020. The amendments...Read more
Marietta, Ohio, July 7, 2020                                                                                                                ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX), a clinical-stage biomedical company, provides the following update regarding upcoming news in its Dry Eye...Read more
Marietta, Ohio, April 6, 2020                                                                                                               ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX), a clinical-stage biomedical company, having recently announced filing for patent protection for new applications of...Read more
Marietta, Ohio, March 24, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced an update to the Press Release of January 24, 2020....Read more

Subscribe for updates

Get alerts about company news and key findings directly in your inbox.

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.

Picture of a molecule
Picture of a molecule